Phase II Study to evaluate the efficacy and safety of bioadhesive barrier-forming oral liquid gel (Episil) for prevention of oral mucositis in patients who are receiving chemotherapy (In DFP therapy of esophageal cancer)

Takano HIdeyuki0 个研究点目标入组 50 人开始时间: 2022年5月30日最近更新: 2023年10月17日

试验速览

暂无简介。

•1.Patients who are histologically diagnosed as squamous cell carcinoma, adenosquamous carcinoma, or basal cell carcinoma by endoscopic biopsy of the primary esophageal lesion
•2.Patients whose treatment policy in esophageal surgery is preoperative chemotherapy with DFP and surgery
•3.Patients whose Performance status (PS) is 0, 1 or 2 according to ECOG criteria
•4.Patients who have written consent to participate in the study

•1.Patients with cancer lesions in the oral cavity
•2.Patients with obvious wounds in the oral cavity other than oral mucositis
•3.Patients known to be allergic to the components of Epicil
•4.Patients participating in other clinical trials or clinical studies
•5.Female patients who are breastfeeding, pregnant, or may become pregnant
•6.In addition, patients who find it difficult to carry out this study at the discretion of the researcher

发起方

Takano HIdeyuki